SGLT2 inhibition and chronic kidney disease outcomes: in diabetes and beyond

SGLT2 inhibition and chronic kidney disease outcomes: in diabetes and beyond

Chronic kidney disease (CKD) is a pressing public health concern. CKD attributed to diabetes, known as diabetic kidney disease (DKD), is the most common cause of kidney failure, accounting for half of all cases. ^{1, 2}  As the number of people with diabetes dramatically rises around the world, the burden of diabetic complications will concurrently swell. Occurring in about 30% of patients with type 1 diabetes and 40% of those with type 2 diabetes, DKD is one of most incapacitating and lethal complications of diabetes. ¹  Additionally, about a quarter of cases of kidney failure in CKD are attributed to hypertension, followed by various forms of glomerular diseases. ²  It is crucial to recognise that the risks of CKD include a high risk of death that outcompetes risk of progression to kidney failure, particularly in patients with diabetes. ³
Indeed, most people with CKD die before progressing to kidney failure. The largest number of deaths in people with CKD are due to cardiovascular diseases, especially heart failure. ^{1 , 2}  In order to meaningfully improve patient outcomes—survival without kidney failure or heart failure—better CKD care is urgently needed.


 Access full article